International journal of clinical practice
-
Int. J. Clin. Pract. · Oct 2020
Early Biomarkers of Diabetic Kidney Disease. A focus on albuminuria and a new combination of antidiabetic agents.
We aimed to determine the efficacy and safety of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists to prevent worsening urinary albumin-to-creatinine ratio as an early biomarker of diabetes kidney disease. ⋯ Our results show the beneficial effect of GLP1ra and SGLT2i combination therapy on early biomarkers of diabetes kidney disease such as albuminuria and in other significant outcomes for diabetes control.